Withdrawal of Dupilumab in Severe Asthma
NCT06818019
Summary
Asthma management has been revolutionised by the development of biological therapies. Dupilumab is an anti-interleukin4 receptor marketed in 2020 for severe asthmatic patients with 2 exacerbations or more within the last 12 months. Although data showed that safety and efficacy of dupilumab are sustained when treatment is extended up to 3 years, no study has emerged regarding dupilumab discontinuation. This study aims to demonstrate the non-inferiority regarding strategy failure at 24 months of stopping dupilumab (intervention group) compared with its continuation (control group) in controlled asthma patients receiving this drug for at least 3 years.
Eligibility
Inclusion Criteria: * Adult patients ≥ 18 years old * Treated with dupilumab for at least 36 months for severe asthma * Well controlled asthma defined by an Asthma Control Questionnaire score ≥ 18 and 0 or 1 exacerbation within the year prior to the inclusion visit Exclusion Criteria: * Patients who refuse to discontinue dupilumab, for any reason * Patients with Forced expiratory volume in one second ≤ 30% of predicted values * Patients treated by an oral corticosteroid dose ≥ 10 mg/day (in prednisone equivalent) * Patients who have to discontinue dupilumab for a reason other than controlled asthma, such as an adverse drug reaction, a planned or current pregnancy, or a planned switch to another biologic indicated in severe asthma * Patients who have to continue dupilumab for the treatment of comorbidities apart from nasal polyposis * Active smoking * Pregnancy or breastfeeding
Conditions2
Interventions1
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT06818019